|Min SIP Amount||₹1000|
|NAV||₹23.15 (14 Jun 2021)|
|Fund Started||25 Jun 2018|
|Fund Size||₹1,595 Cr|
|Sun Pharmaceutical Inds. Ltd.||Healthcare||Equity||11.7%|
|Dr. Reddy's Laboratories Ltd.||Healthcare||Equity||10.1%|
|Divi's Laboratories Ltd.||Healthcare||Equity||8.6%|
|Torrent Pharmaceuticals Ltd.||Healthcare||Equity||5.5%|
|Ipca Laboratories Ltd.||Healthcare||Equity||5.1%|
|Apollo Hospitals Enterprise Ltd.||Healthcare||Equity||4.8%|
|Aurobindo Pharma Ltd.||Healthcare||Equity||4.7%|
|Natco Pharma Ltd.||Healthcare||Equity||3.7%|
Mirae Asset Healthcare Fund Direct Growth is a Equity Mutual Fund Scheme launched by Mirae Asset Mutual Fund. This scheme was made available to investors on 25 Jun 2018. Neelesh Surana is the Current Fund Manager of Mirae Asset Healthcare Fund Direct Growth fund.The fund currently has an Asset Under Management(AUM) of ₹1,595 Cr and the Latest NAV as of 14 Jun 2021 is ₹23.15.
The Mirae Asset Healthcare Fund Direct Growth is rated Very High risk. Minimum SIP Investment is set to 1000. Minimum Lumpsum Investment is 5000. Exit load of 1% if redeemed within 1 year.
The scheme seeks to generate long term capital appreciation through investing in equity and equity related securities of companies benefitting directly or indirectly in Healthcare and allied sectors in India.
Returns are taxed at 15%, if you redeem before one year. After 1 year, you are required to pay LTCG tax of 10% on returns of Rs 1 lakh+ in a financial year.